You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
聯邦製藥(03933.HK)與諾和諾德訂立獨家許可協定
格隆匯 03-24 18:05

格隆匯3月24日丨聯邦製藥(03933.HK)公佈,於2025年3月24日,公司全資附屬公司聯邦生物科技(珠海橫琴)有限公司及公司已與諾和諾德股份有限公司訂立獨家許可協定。該協議涉及UBT251,一種GLP-1受體(胰高血糖素樣肽-1)、GIP受體(葡萄糖依賴性促胰島素多肽)和胰高血糖素受體的三重激動劑,處於早期臨牀開發階段,用於治療肥胖、2型糖尿病和其他疾病。

根據獨家許可協議,諾和諾德將獲得全球(不包括中國大陸、香港特別行政區、澳門特別行政區和臺灣)開發、製造和商業化UBT251的權利。聯邦生物科技將保留UBT251在中國大陸、香港特別行政區、澳門特別行政區和臺灣地區的權利。

根據獨家許可協議並受其條款和條件約束,聯邦生物科技將有資格收取2億美元的預付款和最高18億美元的潛在里程碑付款,視達成若幹開發和銷售里程碑而定,以及可收取基於該地區的年度淨銷售額計算的分層銷售提成。

UBT251是一種靶向GLP-1、GIP和胰高血糖素受體的長效合成肽三重激動劑,在臨牀前環境中已顯示出對所有三種受體的有效活性。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account